Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant 2018
2018 Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab 2018
2016 A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases 2016
2016 MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. 2016
2014 MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations 2014
2014 Pazopanib combined with radiation: In vivo model of interaction 2014
2014 Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients 2014
2014 Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab 2014
2013 MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications 2013
2013 Phase i study of a modified regimen of 90yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed cd20+ non-hodgkin lymphoma 2013
2013 Multiple myeloma, version 1.2013: Featured updates to the NCCN guidelines 2013
2012 Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013: Featured updates to the NCCN guidelines 2012
2012 Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer 2012
2011 Multiple myeloma clinical practice guidelines in oncology 2011
2011 Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma 2011
2010 Renal dosimetry 2010
2010 Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer 2010
2010 Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and Neck 2010
2010 MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy 2010
2010 Impact of Dose Rate on Outcomes of Gamma Knife® Radiosurgery in Patients with Face Pain 2010
2010 Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma 2010
2010 Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer 2010
2009 Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving Radiation Therapy With or Without Chemotherapy 2009
2009 Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source. 2009
2009 MIRD dose estimate report No. 20: Radiation aBsorbed-dose estimates for 111In-And 90Y-ibritumomab Tiuxetan 2009
2009 MIRD commentary: Proposed name for a dosimetry unit applicable to deterministic biological effects-the barendsen (Bd) 2009
2009 MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature 2009
2009 Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck Cancer 2009
2009 Cancer of the tonsil presenting as central nervous system metastasis: A case report 2009
2009 Dose optimization of breast balloon brachytherapy using a stepping 192 Ir HDR source 2009
2009 Multiple myeloma 2009
2008 MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response - Implications for radionuclide therapy 2008
2008 Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma 2008
2008 Risks to Normal Tissues From Radionuclide Therapy 2008
2008 Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment 2008
2008 Targeted radionuclide therapy. 2008
2008 Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck 2008
2008 A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae 2008
2008 Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone 2008
2008 Targeted radionuclide therapy 2008
2007 Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer 2007
2007 Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma 2007
2007 Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03 2007
2007 Microvessel density ≥60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: Results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 trial 2007
2007 Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire 2007
2006 Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy 2006
2006 Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma 2006
2006 Logistics of therapy with the ibritumomab tiuxetan regimen 2006
2006 Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma 2006
2006 Overview of dosimetry for systemic targeted radionuclide therapy (STaRT) 2006
2006 Pretargeted radioimmunotherapy 2006
2006 Summary of systemic targeted radionuclide therapy symposium 2006
2006 Systemic Targeted Radionuclide Therapy symposium introduction 2006
2006 Effect of pilocarpine during radiation therapy: Results of RTOG 97-09, a phase III randomized study in head and neck cancer patients 2006
2006 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy 2006
2005 Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies 2005
2005 Reply [2] 2005
2005 Phase I study of90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration 2005
2005 Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein 2005
2005 Clinically useful marrow dosimetry for targeted radionuclide therapy 2005
2005 Testicular uptake and radiation dose in patients receiving Zevalin™ and Pretarget™ CC49Fusion protein 2005
2004 Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison 2004
2004 Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma 2004
2003 P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003 2003
2003 Phase III quality-of-life study results: Impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer - RTOG 97-09 2003
2003 Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer 2003
2003 A Novel Monoclonal Antibody Design for Radioimmunotherapy 2003
2003 Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy 2003
2003 Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy 2003
2002 Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting90Y-antibody therapy 2002
2002 Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: Long-term follow-up of a phase I trial 2002
2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy. 2002
2002 Rationales, evidence, and design considerations for fractionated radioimmunotherapy. 2002
2002 A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer 2002
2001 Radioimmunotherapy of B-cell NHL 2001
2001 RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck 2001
2001 Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study 2001
2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer 2001
2000 Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. 2000
2000 Clinical radioimmunotherapy 2000
1999 A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy. 1999
1999 Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. 1999
1999 Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck 1999
1999 Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation 1999
1998 Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with 177Lu-CC49 1998
1998 Chimeric antibodies with specificity for tumor antigens: Demonstration of in situ localization to tumors after antibody therapy 1998
1997 Recent Progress in Radioimmunotherapy for Cancer 1997
1997 Sucralfate for radiation mucositis: Results of a double-blind randomized trial 1997
1997 Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials 1997
1997 Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49: A phase I/II study 1997
1996 Phase II study of dual131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer 1996
1996 Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177- CC49 1996
1996 Major geometric variations between intracavitary applications in carcinoma of the cervix: High dose rate vs. Low dose rate 1996
1996 Postsurgical recurrent carcinoma of the cervix: Reassessment and results of radiation therapy options 1996
1995 Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer 1995
1995 Fractionated radioimmumotherapy of human colon carcinoma xenografts with131I-labeled monoclonal antibody CC49 1995
1995 Conventional four-field pelvic radiotherapy technique without computed tomography-treatment planning in cancer of the cervix: Potential geographic miss and its impact on pelvic control 1995
1995 Major geometric variations between multiple high-dose-rate applications of brachytherapy in cancer of the cervix: Frequency and types of variation 1995
1994 Conventional four-field pelvic radiotherapy technique without CT treatment planning in cancer of the cervix: potential geographic miss 1994
1994 Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49 1994
1993 Malignant epidural spinal cord compression associated with a paravertebral mass: Its radiotherapeutic outcome on radiosensitivity 1993
1993 A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1 1993
1993 Comparison of diagnostic and therapeutic doses of 131I-LYM-1 in patients with non-Hodgkin's lymphoma 1993
1993 Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer 1993
1993 Dosimetry of solid tumors 1993
1993 Effect of Human immune response on repeat courses of131I-Chimeric B72.3 antibody therapy 1993
1992 A Phase I study of high-dose cisplatin, prolonged infusion 5- fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck 1992
1992 Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer 1992
1992 Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer 1992
1992 Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation 1992
1991 Pharmacokinetics and Immune Response of 131I-ChimericMouse/Human B72.3 (Human 74) Monoclonal Antibody in Humans 1991
1991 A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck 1991
1991 Expedient set-up of tangential breast fields with a simple gantry attachment 1991
1991 Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody 1991
1991 Three-port perineal sparing technique 1991
1990 Extradural spinal cord compression: Analysis of factors determining functional prognosis - Prospective study 1990
1990 Hyperthermia of pet animal tumours with self-regulating ferromagnetic thermoseeds 1990
1990 The changing face of radiation oncology 1990
1989 Ferromagnetic thermoseeds: Suitable for an afterloading interstitial implant 1989
1989 Practical aspects of ferromagnetic thermoseed hyperthermia 1989
1987 1986 Association of residents in radiation oncology survey 1987
1986 An excess of uterine sarcomas after pelvic irradiation. 1986
1986 Beta-chain human chorionic gonadotropin-producing leiomyosarcoma of the small intestine. 1986
1986 An excess of uterine sarcomas after pelvic irradiation 1986
1986 Beta‐chain human chorionic gonadotropin‐producing leiomyosarcoma of the small intestine 1986
1983 Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation 1983
1982 Possibility of three distinct and separable components to fatal graft-vs-host reaction 1982
1982 Effects of piperazinedione (NSC 135785) plus irradiation on endogenous CFU-S, intestinal crypts, and as a possible ablative protocol for marrow transplantation as evaluated in Rauscher leukemic mice 1982
1981 Graft-vs-leukemia and moderation of graft-vs-host reaction in transplantation therapy of viral leukemia 1981
1981 Histocompatibility influence in allogeneic marrow transplantation therapy of murine viral leukemia. I.--Studies of the relative influence of major versus minor histocompatibility determinants. 1981
1981 Fatal response suggestive of graft-versus-host reaction following transplantation of spleen cells from allogeneic athymic (Nude) donors 1981
1980 Methyl methane sulfonate induced enhancement of Friend viral leukemogenesis 1980
1980 Exponential relationship between spleen cell concentration and fatal graft-versus-host response after transplantation of allogeneic spleen-marrow cell mixtures 1980
1980 Rauscher Leukemia as a Model for Cancer Therapy Studies. II. Variation in Response of Splenic CFU-S between Normal and Rauscher Leukemic Mice following Exposure to Hydroxyurea 1980
1979 Cyclophosphamide/X-ray: Combined mode preparation for transplantation therapy 1979
1979 Effect of piperazinedione (NSC 135758) and irradiation combined treatment on stem cell populations in normal and leukemic mice 1979
1979 Improving transplantation therapy of leukemia: A new model for testing marrow ablative pretreatments 1979
1979 Potentiating Effect of Methyl Methane Sulfonate on Friend Virus Leukemogenesis in Vivo 1979
1979 Rauscher leukemia as a model for studies of marrow transplantation therapy: Results using syngeneic, allogeneic and hybrid donors 1979
1978 Successful therapy of viral leukemia by transplantation of histocompatibility unmatched marrow 1978
1978 Comparison of cyclophosphamide and/or X irradiation in the preparation of viral leukemic mice for marrow transplantation therapy 1978
1978 Contrasting immune response following Rauscher leukemia virus infection in virus-susceptible vs. virus-resistant mice 1978
1978 Stimulation of Immune Response in Hybrid Mice Following Rauscher Virus Infection 1978
1976 Genetic influence in murine viral leukemogenesis 1976
1975 THE GENETIC BASIS OF MALE POTENCY IN VOLVOX CARTERI F. NAGARIENSIS (CHLOROPHYCEAE) 1975

Chapter

Year Title Altmetric
2012 Toxicity due to systemic radiotherapy.  351-366. 2012
2011 Targeted Radionuclide Therapy.  405-419. 2011
2011 Targeted Radionuclide Therapy.  e22_1-e22_46. 2011
2010 Impact of dose rate on outcomes of Gamma Knife ® radiosurgery in patients with face pain.  360-365. 2010
2009 Targeted radionuclide therapy of cancer.  463-496. 2009
2000 Radionuclide dosimetry and radioimmunotherapy of cancer.  21-55. 2000

Research Overview

  • My current emphasis is use of my basic science background in the development of clinical trials for cancer patients. Currently, breast cancer, non-Hodgkin's lymphomas, and radionuclide therapy are my primary treatment areas.

    • Principal Investigator On

  • Private Grant  awarded by AREVA ENTERPRISES, INC. 2011 - 2016
  • Private Grant  awarded by IMCLONE SYSTEMS, INC. 2008 - 2012
  • Radiation Therapy Oncology Group  awarded by American College of Radiology 1995 - 2010

    • Investigator On

  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology 2012 - 2022
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Racial Disparities: Pain in Women Treated for Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS 2016
  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953  awarded by Johns Hopkins University 2009 - 2015
  • Targeting Signal Transduction Pathways for the Treatment and Prevention of Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2012 - 2014
  • ACRIN 6668: Positron Emission Tomography Pre & Post Treatment Assessment for Locally Advanced Non-Small Cell Lung Carcinoma  awarded by AMERICAN CARDIOVASCULAR RESEARCH INSTITUTE 2005 - 2013
  • Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2011 - 2012

    • Education And Training

  • Doctor of Medicine, Ohio State University System : Columbus 1983
  • Doctor of Philosophy in Botany / Plant Biology, Indiana University System : Indiana University-Bloomington 1983
  • Medical College of Virginia Hospital, Internship 1984
  • Medical College of Virginia Hospital, Residency 1987

    • Full Name

  • Ruby Meredith